FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322775488> ?p ?o ?g. }

• W4322775488 endingPage "23" @default.
• W4322775488 startingPage "P5" @default.
• W4322775488 abstract "Abstract Background: Pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) are putative prognostic factors in patients with advanced breast cancer (ABC). Little information is available on the prognostic value of these immune status markers in patients treated with abemaciclib (ABE). In this study, we investigated the relationship between baseline NLR and ALC and clinical outcomes using data from the phase 3 MONARCH 2 (M2) trial. Methods: The M2 study compared ABE/fulvestrant to placebo (PBO)/fulvestrant in patients with estrogen-receptor positive, human epidermal growth factor receptor 2-negative ABC that had progressed on prior endocrine therapy. The current post hoc analyses used baseline laboratory data and outcome data from the June 20, 2019, cutoff date (median follow-up: 47.7 months). For both baseline NLR and baseline ALC, patients were divided into high and low categories, defined by a cutoff of 2.5 for NLR and 1.5 × 109/L for ALC. The association of baseline NLR and ALC with investigator-assessed progression-free survival (PFS) and overall survival (OS) was explored using Cox models stratified by treatment and described using Kaplan-Meier estimates. After assessing the prognostic value of baseline NLR and ALC for PFS and OS using a univariate analysis, a multivariate model was used to determine whether baseline NLR and ALC were independently prognostic considering additional baseline and disease characteristic factors. Results: Data were available for 426 and 219 patients in the ABE and PBO arms, respectively. Median baseline NLR was 2.5 and 2.4 in the ABE and PBO arms, respectively. Median baseline ALC was 1.4 × 109/L in both arms. The numbers of patients categorized into the high and low categories were well balanced for analysis of both NLR and ALC. Univariate analyses showed that baseline NLR (&lt; 2.5, ≥2.5) was a prognostic factor for PFS and OS (2-sided p&lt; 0.0001). Patients with low baseline NLR consistently had better PFS and OS than those with high baseline NLR, and the treatment effect of ABE against PBO was consistently observed regardless of NLR category (Table 1). Univariate analyses showed that baseline ALC (&lt; 1.5 × 109/L, ≥1.5 × 109/L) was also a prognostic factor for PFS and OS (2-sided p=0.0116 and 0.0032, respectively). PFS and OS were better for patients with high baseline ALC than for those with low baseline ALC, and the treatment effect of ABE against PBO was observed regardless of ALC category (Table 1). For PFS, the multivariate model was adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS), tumor grade, presence of liver metastasis, and bone-only disease. For OS, the multivariate model was adjusted for sensitivity to endocrine therapy, ECOG PS, presence of liver metastasis, and bone-only disease. When adjusting for these additional prognostic factors, baseline NLR, but not baseline ALC, remained statistically significant in the multivariate model (2-sided p&lt; 0.0001). Conclusions: These exploratory analyses suggest that while both baseline NLR and ALC are prognostic of clinical outcomes, only baseline NLR is independently prognostic of PFS and OS. Low baseline NLR was associated with better PFS and OS outcomes, but the benefit of adding ABE to fulvestrant was similar regardless of baseline NLR status. Table 1. Summary of outcomes by treatment arm for NLR and ALC categories ALC, absolute lymphocyte count; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; NR, not reached; OS, overall survival; PFS, progression-free survival. Citation Format: Eriko Tokunaga, Yasuo Miyoshi, Koji Dozono, Tsutomu Kawaguchi, Masakazu Toi. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count with Clinical Outcomes for Patients with Advanced Breast Cancer in the MONARCH 2 Trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-02-23." @default.
• W4322775488 created "2023-03-03" @default.
• W4322775488 creator A5007690396 @default.
• W4322775488 creator A5009941832 @default.
• W4322775488 creator A5011644667 @default.
• W4322775488 creator A5054758865 @default.
• W4322775488 creator A5091245889 @default.
• W4322775488 date "2023-03-01" @default.
• W4322775488 modified "2023-10-16" @default.
• W4322775488 title "Abstract P5-02-23: Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count with Clinical Outcomes for Patients with Advanced Breast Cancer in the MONARCH 2 Trial" @default.
• W4322775488 doi "https://doi.org/10.1158/1538-7445.sabcs22-p5-02-23" @default.
• W4322775488 hasPublicationYear "2023" @default.
• W4322775488 type Work @default.
• W4322775488 citedByCount "0" @default.
• W4322775488 crossrefType "journal-article" @default.
• W4322775488 hasAuthorship W4322775488A5007690396 @default.
• W4322775488 hasAuthorship W4322775488A5009941832 @default.
• W4322775488 hasAuthorship W4322775488A5011644667 @default.
• W4322775488 hasAuthorship W4322775488A5054758865 @default.
• W4322775488 hasAuthorship W4322775488A5091245889 @default.
• W4322775488 hasConcept C121608353 @default.
• W4322775488 hasConcept C126322002 @default.
• W4322775488 hasConcept C143998085 @default.
• W4322775488 hasConcept C144301174 @default.
• W4322775488 hasConcept C207103383 @default.
• W4322775488 hasConcept C2777761686 @default.
• W4322775488 hasConcept C2778963024 @default.
• W4322775488 hasConcept C2780482068 @default.
• W4322775488 hasConcept C2780739268 @default.
• W4322775488 hasConcept C3019894029 @default.
• W4322775488 hasConcept C38180746 @default.
• W4322775488 hasConcept C44249647 @default.
• W4322775488 hasConcept C50382708 @default.
• W4322775488 hasConcept C530470458 @default.
• W4322775488 hasConcept C67761136 @default.
• W4322775488 hasConcept C71924100 @default.
• W4322775488 hasConcept C84606932 @default.
• W4322775488 hasConceptScore W4322775488C121608353 @default.
• W4322775488 hasConceptScore W4322775488C126322002 @default.
• W4322775488 hasConceptScore W4322775488C143998085 @default.
• W4322775488 hasConceptScore W4322775488C144301174 @default.
• W4322775488 hasConceptScore W4322775488C207103383 @default.
• W4322775488 hasConceptScore W4322775488C2777761686 @default.
• W4322775488 hasConceptScore W4322775488C2778963024 @default.
• W4322775488 hasConceptScore W4322775488C2780482068 @default.
• W4322775488 hasConceptScore W4322775488C2780739268 @default.
• W4322775488 hasConceptScore W4322775488C3019894029 @default.
• W4322775488 hasConceptScore W4322775488C38180746 @default.
• W4322775488 hasConceptScore W4322775488C44249647 @default.
• W4322775488 hasConceptScore W4322775488C50382708 @default.
• W4322775488 hasConceptScore W4322775488C530470458 @default.
• W4322775488 hasConceptScore W4322775488C67761136 @default.
• W4322775488 hasConceptScore W4322775488C71924100 @default.
• W4322775488 hasConceptScore W4322775488C84606932 @default.
• W4322775488 hasIssue "5_Supplement" @default.
• W4322775488 hasLocation W43227754881 @default.
• W4322775488 hasOpenAccess W4322775488 @default.
• W4322775488 hasPrimaryLocation W43227754881 @default.
• W4322775488 hasRelatedWork W1998259048 @default.
• W4322775488 hasRelatedWork W2080756964 @default.
• W4322775488 hasRelatedWork W2361700749 @default.
• W4322775488 hasRelatedWork W2597798031 @default.
• W4322775488 hasRelatedWork W2789279481 @default.
• W4322775488 hasRelatedWork W2801927881 @default.
• W4322775488 hasRelatedWork W2889343797 @default.
• W4322775488 hasRelatedWork W2901430139 @default.
• W4322775488 hasRelatedWork W3095421467 @default.
• W4322775488 hasRelatedWork W3117264097 @default.
• W4322775488 hasVolume "83" @default.
• W4322775488 isParatext "false" @default.
• W4322775488 isRetracted "false" @default.
• W4322775488 workType "article" @default.